North Dakota is currently home to 233 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Fargo, Bismarck, Grand Forks and Minot. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: Sanford Children's Hospital, Fargo, North Dakota
Conditions: Venous Thromboembolism
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Sanford NCORP of the North Central Plains, Fargo, North Dakota
Conditions: Colorectal Cancer
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr
Recruiting
This study will use an adjuvant radiation therapy regimen called APBI (accelerated partial breast irradiation). APBI is a treatment option available to women considered to have an early stage, low-risk breast cancer. The standard external beam-based APBI treatment delivers treatments every other day for five treatments, over ten calendar days. The APBI in this study is modified and will deliver five once daily treatments over consecutive treatment days, with a slightly lower dose of radiation ea... Read More
Gender:
Female
Ages:
50 years and above
Trial Updated:
11/11/2022
Locations: Sanford Health, Fargo, North Dakota
Conditions: Breast Cancer
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Sanford Bismarck Medical Center, Bismarck, North Dakota
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Safety and Efficacy Study of BRIMOCHOLâ„¢ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Recruiting
Safety and Efficacy Study of BRIMOCHOLâ„¢ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Gender:
All
Ages:
Between 45 years and 80 years
Trial Updated:
09/30/2022
Locations: Visus Therapeutics Investigative Site, W. Fargo, North Dakota
Conditions: Presbyopia